VintaBio
VintaBio: Expert CDMO provider for viral vectors, advancing cell and gene therapy manufacturing.
Founded
2020VintaBio: Expert CDMO provider for viral vectors, advancing cell and gene therapy manufacturing.
VintaBio, founded by Dr. Shangzhen Zhou, is a Contract Development and Manufacturing Organization (CDMO) specializing in the production of GMP-grade and research-grade viral vectors. The company’s core mission is to alleviate the viral vector bottleneck in cell and gene therapy development, thereby accelerating the advancement of these transformative therapies. VintaBio provides comprehensive manufacturing services tailored to pharmaceutical and biotechnology organizations, ensuring high-quality vector production and fostering trust and transparency throughout the development process.
Notable affiliated individuals include Dr. Shangzhen Zhou, whose expertise drives the company’s innovative approach. VintaBio has made significant strides in the life sciences sector by addressing critical challenges in cell and gene therapy manufacturing. Their impact is evidenced by their ability to streamline the production process, thereby expediting the delivery of vital therapies to patients. Through their specialized services, VintaBio has positioned itself as a key player in the biopharmaceutical industry, contributing to the advancement of cutting-edge medical treatments.
Companies similar to VintaBio include Vector Biomed, Center for Breakthrough Medicines, Andelyn Biosciences and iVexSol.
VintaBio was founded in 2020.
VintaBio's headquarters is located in Philadelphia, PA, US.
VintaBio's most recent funding round was for $64M (USD) in April 2023.
As of Apr 11, 2023, VintaBio has disclosed funding of $64M (USD). Undisclosed round amounts are excluded.
VintaBio has 15 employees as of Feb 4, 2024.
iVexSol
ivexsol.com
